The technology of tomorrow …

The fastest gateway to a successful launch is by choosing the right lead compound early. N2MO’s ex vivo models can provide guidance to you in your early drug discovery choices!

Contact us

N2MO A/S
Islandsbrygge 79C, 8502
DK-2300 København S
Denmark

Phone: +45 3134 4896

News Room

New management

N2MO has appointed Preben Carøe as new CEO. Preben comes most recently from being Vice President and General Manager at Ametek. In a new position Björn Ursing, PhD, has been appointed COO. He comes most recently from working at Västerbotten Investment Agency in attracting foreign direct investments to northern Sweden.

By |December 7th, 2015|About N2MO|

Notice of Allowance in USA for new ex vivo model patent rights

We are hereby pleased to report that the above referenced patent application has received a Notice of Allowance, indicating that the claims presently on file are allowable.

Our unique ex vivo model described in the USA application “Methods employing insect models for determining intestinal absorption of chemical compounds” is a valuable tool to determinate the profiling of […]

By |August 4th, 2015|Patents|

N2MO Granted Award as Best Investment Opportunity 2015

The Business Angels Networks in Denmark held their annual meeting 2015 in Odense on the 21st. of May. In a very intense competition, N2MO was granted the winning position based on the level of interest in investing in the company. The meeting creates a unique platform for innovative start-up companies to meet with investors as […]

By |June 4th, 2015|About N2MO, Funding|

N2MO is now offering unique ex vivo models for early drug discovery

N2MO is now established in offices north of Copenhagen in the DTU SCION science park in Lyngby.

N2MO is based on 8 unique patents covering ex vivo models for early drug discovery. Through close corporation with academia and the pharmaceutical environment, we have developed Grasshopper ex vivo models enabling measurement on the absorption profile of compounds […]

By |February 24th, 2015|Patents|

Data presented by Lundbeck in Berlin

Lundbeck presented data at the 4th International Conference Clinically Relevant Drug Transporters, 22 – 23 2013 in Berlin

Recent data obtained by using our optimized model was presented by Lundbeck in Berlin at the 4th International Conference Clinically Relevant Drug Transporters – 22 – 23 April, 2013.

In summary the data shows:

that our ex vivo grasshopper model […]

By |April 10th, 2013|Conferences|

Review: Novel Models for Assessing Blood-Brain Barrier Drug Permeation

Have you read the most recent review “Novel Models for Assessing Blood-Brain Barrier Drug Permeation”?
Please find link to the review ‘Novel models for assessing blood–brain barrier drug permeation’ by Geldenhuys et al. (Posted online on April 3 2012, in Expert Opinion on Drug Metabolism & Toxicology

By |May 1st, 2012|Research|

Funding for The Project “Insect Models for Drug Discovery”

The Project “Insect Models for Drug Discovery” has received funding from the Danish National Advanced Technology Foundation.
The vision of the project is to establish insects, as a novel model organism in preclinical research.

EntomoPharm has previously developed two models for ADME drug screening in locusts. From this work and from preliminary insect studies it is evident […]

By |January 2nd, 2012|Funding|

N2MO has been granted European (EPO) Patent

N2MO has been granted European (EPO) Patent for Screening Methods employing insects with Blood Brain Barrier
The patent covers insect models that are aimed to reflect vertebrate blood-brain barrier (BBB) penetration.

The value of the insect BBB model is that it can be just as predictive as expensive and time consuming animal models, and by using the […]

By |May 28th, 2009|About N2MO, Patents|